High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 318-322

  Ishikawa, Tetsuya ^a   Ayaori, Makoto ^b   Uto Kondo, Harumi ^b   Nakajima, Takatomo ^a   Mutoh, Makoto ^a   Ikewaki, Katsunori ^b  

^a Laboratory Medicine   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Coronary artery disease; High density lipoprotein cholesterol efflux capacity; Lipid disorder; Low density lipoprotein cholesterol; Propensity score matching analysis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; APOA1 PROTEIN, HUMAN; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DYSLIPIDEMIA; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROPENSITY SCORE; ANIMAL; AREA UNDER THE CURVE; BLOOD; CELL LINE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DYSLIPIDEMIAS; JAPAN; METABOLISM; MIDDLE AGED; MOUSE; ODDS RATIO; PREDICTIVE VALUE; PROCEDURES; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

AGED; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN B-100; AREA UNDER CURVE; BIOMARKERS; CELL LINE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; DYSLIPIDEMIAS; FEMALE; HUMANS; JAPAN; LOGISTIC MODELS; MACROPHAGES; MALE; MICE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84938239687     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.028     Document Type: Article

References (19)

1. Stone N.J., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014, 129(25 Suppl.2):S1-S45. [Epub 12.11.13]. 10.1161/01.cir.0000437738.63853.7a.
2. Yokoyama S., et al. Background to discuss guidelines for control of plasma HDL-choleterol in Japan. J.Atheroscler. Thromb. 2012, 19:207-212. [Epub 12.01.12].
3. Gordon D.J., et al. High-density lipoprotein: the clinical implications of recent studies. N.Engl. J. Med. 1989, 321:1311-1316.
4. Kitamura A., et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994, 89:2533-2539.
5. Boden W.E., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267. [Epub 15.11.11]. 10.1056/NEJMoa1107579.
6. HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291. HPS2-THRIVE Collaborative Group, [Epub 26.02.13]. 10.1093/eurheartj/eht055.
7. Kastelein J.J., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N.Engl. J. Med. 2007, 356:1620-1630.
8. Schwartz G.G., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N.Engl. J. Med. 2012, 367:2089-2099. [Epub 05.11.12]. 10.1056/NEJMoa1206797.
9. Movva R., et al. Laboratory assessment of HDL heterogeneity and function. Clin. Chem. 2008, 54:788-800. [Epub 28.03.08]. 10.1373/clinchem.2007.101923.
10. Khera A.V., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N.Engl. J. Med. 2011, 364:127-135.
11. Austen W.G., et al. Areporting system on patients evaluated for coronary artery disease. report of the Ad Hoc committee for grading of coronary artery disease, council on cardiovascular surgery, American heart association. Circulation 1975, 51(4 Suppl.l):5-40.
12. Cui R., et al. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese. Atherosclerosis 2007, 194:415-420. [Epub 12.09.06].
13. Sarwar N., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Triglyceride coronary disease genetics consortium and emerging risk factors collaboration. Lancet 2010, 375:1634-1639. 10.1016/S0140-6736(10)60545-4.
14. Endo A., et al. Contributors to newly developed coronary artery disease in patients with a previous history of percutaneous coronary intervention beyond the early phase of restenosis. Intern Med. 2014, 53:819-828. [Epub 15.04.14].
15. Okamura T., et al. Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort: the suita study. Atherosclerosis 2010, 209:290-294. [Epub 12.09.09]. 10.1016/j.atherosclerosis.2009.09.012.
16. Ralph B., et al. Propensity scores in cardiovascular research. Circulation 2007, 115:2340-2343.
17. Berrougui H., et al. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res. 2009, 12:117-126. 10.1089/rej.2008.0840.
18. Zhou H., et al. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab. Res. Rev. 2008, 24:617-623.
19. Miyamoto-Sasaki M., et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J.Atheroscler. Thromb. 2013, 20:708-716. [Epub 05.06.13].